Sagent Pharmaceuticals, Inc. - FORM 10-Q

Sagent Pharmaceuticals, Inc. - FORM 10-Q - November 3, 2015

Attached files

Attached files

Sagent Pharmaceuticals, Inc. Reports

file	filename
EX-32.1 - EX-32.1 - Sagent Pharmaceuticals, Inc.	d74493dex321.htm
EX-31.1 - EX-31.1 - Sagent Pharmaceuticals, Inc.	d74493dex311.htm
EX-31.2 - EX-31.2 - Sagent Pharmaceuticals, Inc.	d74493dex312.htm
EX-10.1 - EX-10.1 - Sagent Pharmaceuticals, Inc.	d74493dex101.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark

One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-35144

Sagent Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware		98-0536317
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

1901 N. Roselle Road, Suite 700

Schaumburg, Illinois

60195

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (847) 908-1600

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

At October 30, 2015, there were 32,787,344 shares of the registrant’s common stock outstanding.

Sagent Pharmaceuticals, Inc.

Table of Contents


		Page No.
PART I –	FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets at September 30, 2015 and December 31, 2014		1

	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2015 and 2014		2

	Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2015 and 2014		3

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014		4

	Notes to Condensed Consolidated Financial Statements		5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk		32

Item 4.	Controls and Procedures		32

PART II –	OTHER INFORMATION		34

Item 1.	Legal Proceedings		34

Item 1A.	Risk Factors		34

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		35

Item 3.	Defaults Upon Senior Securities		35

Item 4.	Mine Safety Disclosures		35

Item 5.	Other Information		35

Item 6.	Exhibits		35

	Signature		36

In this report, “Sagent,” “we,” “us,” “our” and the “Company” refers to Sagent Pharmaceuticals, Inc. and subsidiaries, and “Common Stock” refers to Sagent’s common stock, $0.01 par value per share.

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)


	September 30, 2015			December 31, 2014
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	25,850		$	55,633
Short-term investments		20,160			18,473
Accounts receivable, net of chargebacks and other deductions		43,043			42,780
Inventories, net		76,228			61,781
Due from related party		2,664			2,156
Current deferred tax assets		9,193			12,135
Prepaid expenses and other current assets		8,436			5,560

Total current assets		185,574			198,518
Property, plant, and equipment, net		68,163			71,153
Investment in joint ventures		6,049			4,539
Goodwill		24,953			28,155
Intangible assets, net		58,200			65,575
Non-current deferred tax assets		14,466			13,173
Other assets		2,204			375

Total assets	$	359,609		$	381,488


Liabilities and stockholders’ equity
Current liabilities:
Accounts payable		36,402		$	32,710
Due to related party		11,573			8,079
Accrued profit sharing		7,245			10,684
Accrued liabilities		15,113			19,346
Current portion of deferred purchase consideration		—			8,725
Current portion of long-term debt		238			508
Notes payable		—			5,499

Total current liabilities		70,571			85,551

Long term liabilities:
Long-term debt		1,500			1,945
Deferred income taxes		12,331			15,706
Other long-term liabilities		2,388			2,534

Total liabilities		86,790			105,736

Stockholders’ equity:
Common stock—$0.01 par value, 100,000,000 authorized, and 32,786,873 and 31,976,661 outstanding at September 30, 2015 and December 31, 2014, respectively		328			320
Additional paid-in capital		365,236			352,982
Accumulated other comprehensive income (loss)		(14,625	)		(3,374	)
Accumulated deficit		(78,120	)		(74,176	)

Total stockholders’ equity		272,819			275,752


Total liabilities and stockholders’ equity	$	359,609		$	381,488

See accompanying notes to condensed consolidated financial statements.

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(Unaudited)


	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Net revenue	$	75,199		$	65,359		$	235,188		$	205,422
Cost of sales		50,837			46,589			170,461			143,676

Gross profit		24,362			18,770			64,727			61,746
Operating expenses:
Product development		7,923			3,677			18,658			17,734
Selling, general and administrative		11,403			10,914			35,886			31,622
Acquisition-related costs		535			872			1,856			872
Management transition costs		645			—			4,647			—
Equity in net (income) of joint ventures		(333	)		(737	)		(1,510	)		(2,476	)

Total operating expenses		20,173			14,726			59,537			47,752

Legal settlement		2,447			—			2,447			—
Income from operations		1,742			4,044			2,743			13,994
Interest income and other income (expense), net		(1,686	)		(536	)		(2,225	)		(465	)
Interest expense		(188	)		(195	)		(650	)		(641	)

Income (loss) before income taxes		(132	)		3,313			(132	)		12,888
Provision for income taxes		1,663			1,387			3,813			2,774

Net income (loss)	$	(1,795	)	$	1,926		$	(3,945	)	$	10,114


Net income (loss) per common share:
Basic	$	(0.05	)	$	0.06		$	(0.12	)	$	0.32
Diluted	$	(0.05	)	$	0.06		$	(0.12	)	$	0.31

Weighted-average of shares used to compute net income per common share:
Basic		32,747			31,895			32,321			31,861
Diluted		32,747			32,960			32,321			32,748

See accompanying notes to condensed consolidated financial statements.

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Income

(in thousands, except per share amounts)

(Unaudited)


	Three months ended September 30,						Nine months ended September 30,
	2015			2014			2015			2014
Net income (loss)	$	(1,795	)	$	1,926		$	(3,945	)	$	10,114
Other comprehensive income (loss), net of tax
Foreign currency translation adjustments		(6,509	)		(2	)		(11,281	)		(448	)
Reclassification of unrealized losses on available for sale securities		—			49			—			49
Unrealized gains (losses) on available for sale securities		5			(101	)		30			(22	)

Total other comprehensive income (loss), net of tax		(6,504	)		(54	)		(11,251	)		(421	)

Comprehensive income (loss)	$	(8,299	)	$	1,872		$	(15,196	)	$	9,693

See accompanying notes to condensed consolidated financial statements

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)


	Nine months ended September 30,
	2015			2014
Cash flows from operating activities
Net income (loss)	$	(3,945	)	$	10,114
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		8,796			6,307
Stock-based compensation		2,845			3,657
Equity in net (income) loss of joint ventures		(1,510	)		(2,476	)
Deferred income taxes, net		457			—
Other		232			(200	)
Changes in operating assets and liabilities:
Accounts receivable, net		(760	)		(10,848	)
Inventories, net		(16,263	)		3,180
Prepaid expenses and other current assets		(2,988	)		1,887
Due from related party		(507	)		(728	)
Accounts payable and other accrued liabilities		755			8,574

Net cash provided by (used in) operating activities		(12,888	)		19,467


Cash flows from investing activities
Capital expenditures		(5,057	)		(2,875	)
Acquisition of business, net of cash acquired		(11,785	)		(3,500	)
Purchases of investments		(10,202	)		(80,998	)
Sale of investments		8,320			174,722
Purchase of product rights		(1,109	)		(2,863	)

Net cash provided by (used in) investing activities		(19,833	)		84,486


Cash flows from financing activities
Reduction in short-term borrowings		(5,189	)		—
Repayment of long-term debt		(411	)		(10,324	)
Payment of deferred financing costs		(199	)		(75	)
Proceeds from issuance of common stock, net of issuance costs		9,417			425

Net cash provided by (used in) financing activities		3,618			(9,974	)

Effect of exchange rate movements in cash		(680	)		(31	)

Net increase (decrease) in cash and cash equivalents		(29,783	)		93,948
Cash and cash equivalents, at beginning of period		55,633			42,332

Cash and cash equivalents, at end of period	$	25,850		$	136,280


Supplemental disclosure of cash flow information
Acquisition of property, plant and equipment in accounts payable		(581	)		—
Acquisition of product licensing rights not yet settled		(1,076	)		—

See accompanying notes to condensed consolidated financial statements

Sagent Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(in thousands, except for share and per share information)

(Unaudited)

Note 1. Basis of presentation:

Our interim condensed consolidated financial statements are unaudited. We prepared the condensed consolidated financial statements following rules for interim reporting as prescribed by the U.S. Securities and Exchange Commission (“SEC”). As permitted under those rules, we have condensed or omitted a number of footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). It is management’s opinion that these financial statements include all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of our financial position, operating results and cash flows. Operating results for any interim period are not necessarily indicative of future or annual results.

The condensed consolidated financial statements include Sagent as well as our wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. We account for our investment in Sagent Agila LLC (formerly Sagent Strides LLC) using the equity method of accounting, as our interest in the entity provides for joint financial and operational control.

You should read these statements in conjunction with our consolidated financial statements and related notes for the year ended December 31, 2014, included in our most recent Annual Report on Form 10-K filed with the SEC on March 16, 2015.

Note 2. Recent Accounting Pronouncements

In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In July 2015, the FASB approved a one year deferral to the new revenue guidance, and are therefore required to adopt the new guidance on January 1, 2018 using one of the two prescribed retroactive methods. We are evaluating the impact of the amended revenue recognition guidance on our consolidated financial statements.

In February 2015, the FASB issued amended guidance on the model used to evaluate whether certain legal entities should be consolidated. This guidance is effective for the Company in the first quarter of 2017. Early adoption is permitted. We are currently evaluating the impact that adoption of this guidance will have on our consolidated financial statements.

In September 2015, the FASB issued guidance that eliminates the requirement to restate prior period financial statements for measurement period adjustments related to business combinations. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. In addition, separate presentation on the face of the income statement or disclosure in the notes to the financial statements is required regarding the portion of the adjustment recorded in current period earnings. We are required to adopt this guidance prospectively for measurement period adjustments that occur after the effective date. This guidance is effective for the Company in the first quarter of 2016. Early adoption is permitted. We have adopted this guidance in the current period. There was no material impact of adoption.

Note 3. Acquisitions:

Omega Acquisition

On October 1, 2014, we, through our wholly-owned Canadian subsidiary, Sagent Acquisition Corp., entered into a Share Purchase Agreement to acquire all of the issued and outstanding shares of the capital stock of 7685947 Canada Inc., and its subsidiary, Omega Laboratories Limited (collectively, “Omega”), a privately held Canadian pharmaceutical and specialty healthcare products company for C$92,768 ($82,693), after accounting for net post-closing adjustments of C$191 ($170). In September 2015, we finalized the post-closing adjustments resulting in a reduction of total purchase consideration of C$241 ($215).

The fair value of identifiable assets acquired and liabilities assumed for the Omega acquisition is shown in the table below:


	(in thousands)
Cash	$	3
Accounts receivable, net		3,419
Inventory		14,014
Prepaid and other current assets		1,295
Property, plant and equipment		14,307
Definite-lived intangible assets		49,918
In-process research and development		7,666
Goodwill		22,842
Accounts payable		(2,410	)
Other accrued liabilities		(4,090	)
Long-term debt and notes payable		(7,095	)
Deferred income tax liabilities		(17,176	)

Total allocation of fair value	$	82,693

We recorded goodwill of $22,842 at the time of acquisition due to the synergies achieved by having control over the products and manufacturing at Omega. We reduced goodwill in September 2015 to reflect the final post-closing adjustment to total purchase consideration of $215.

The following unaudited pro forma financial information reflects the consolidated results of operations of Sagent as if the Omega acquisition had taken place on January 1, 2014. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transaction been effected on the assumed date.


Condensed consolidated statement of operations information	Three months ended September 30, 2014		Nine months ended September 30, 2014
Net revenues	$	72,541	$	229,292
Net income		3,050		8,526
Diluted net income per common share	$	0.09	$	0.26

Product rights acquisitions

On August 5, 2015, we entered into and closed an agreement with Mustafa Nevzat Ilac Sanayii A.S., a subsidiary of Amgen, Inc., (“MN”) to acquire the rights to three products: Methylprednsilone Sodium Succinate, Vecuronium and Pamidronate Disodium. The total fair value of consideration transferred was $3,000, consisting of cash. The product rights have been recognized in our Sagent US segment.

The transaction was accounted for as a purchase of a business. The acquisition of these three products provides us with full control of and access to the product rights. The acquisition was financed with cash. Acquisition related costs related to this transaction were nominal. The weighted average life of these three acquired products rights is approximately 84 months.

The estimated fair value of identifiable assets acquired for these product rights is shown in the table below:


	(in thousands)
Definite-lived intangible assets	$	3,000

Total allocation of fair value	$	3,000

Note 4. Investments:

Our investments at September 30, 2015 were comprised of the following:


	Cost basis		Unrealized gains		Unrealized losses			Carrying value		Cash and cash equivalents		Short term investments
Assets
Cash	$	5,991	$	—	$	—		$	5,991	$	5,991	$	—
Money market funds		19,859		—		—			19,859		19,859		—
Corporate bonds and notes		20,170		1		(11	)		20,160		—		20,160

	$	46,020	$	1	$	(11	)	$	46,010	$	25,850	$	20,160

Investments with continuous unrealized losses for less than twelve months and their related fair values at September 30, 2015 were as follows:


	Fair value		Unrealized losses
Corporate bonds and notes	$	12,481	$	(11	)

Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. Because we do not currently intend to sell these investments, and it is not more likely than not that we will be required to sell our investments before recovery of their amortized cost basis, which may be maturity, we do not consider these investments to be other-than-temporarily impaired at September 30, 2015.

The original cost and estimated current fair value of our fixed-income securities at September 30, 2015 are set forth below.


	Cost basis		Estimated fair value
Due in one year or less	$	12,458	$	12,457
Due between one and five years		7,711		7,703

	$	20,170	$	20,160

Note 5. Inventories:

Inventories at September 30, 2015 and December 31, 2014 were as follows:


	September 30, 2015								December 31, 2014
	Approved			Pending regulatory approval		Inventory			Approved			Pending regulatory approval		Inventory
Raw materials	$	9,356		$	2,818	$	12,174		$	10,203		$	2,848	$	13,051
Work in process		653			—		653			2,012			—		2,012
Finished goods		67,411			—		67,411			49,960			—		49,960
Inventory reserve		(4,010	)		—		(4,010	)		(3,242	)		—		(3,242	)

	$	73,410		$	2,818	$	76,228		$	58,933		$	2,848	$	61,781

Note 6. Property, plant and equipment

Property, plant and equipment at September 30, 2015 and December 31, 2014 were as follows:


	September 30, 2015			December 31, 2014
Land and land improvements	$	3,282		$	3,519
Buildings and improvements		25,523			26,605
Machinery, equipment, furniture and fixtures		44,212			42,124
Construction in process		5,838			6,175

		78,855			78,423
Less accumulated depreciation		(10,692	)		(7,270	)

	$	68,163		$	71,153

Depreciation expense was $1,436 and $4,166 for the three and nine months ended September 30, 2015, respectively.

Note 7. Goodwill and Intangible assets, net:

Goodwill at September 30, 2015 and December 31, 2014 was $24,953 and $28,155, respectively. There were no goodwill impairment losses for the three or nine months ended September 30, 2015 and 2014, respectively.

Movements in goodwill were due to the following:


December 31, 2014	$	28,155
Omega post-closing adjustment		(215	)
Foreign currency translation impact		(2,987	)

September 30, 2015	$	24,953

Intangible assets at September 30, 2015 and December 31, 2014 were as follows:


	September 30, 2015							December 31, 2014
	Gross carrying amount		Accumulated amortization			Intangible assets, net		Gross carrying amount		Accumulated amortization			Intangible assets, net
Product licensing rights	$	4,533	$	(2,900	)	$	1,633	$	4,707	$	(2,878	)	$	1,829
Product development rights		4,500		—			4,500		4,191		—			4,191
Purchased product rights and other		47,635		(4,237	)		43,398		51,245		(1,375	)		49,870

Total definite-lived intangible assets	$	56,668	$	(7,137	)	$	49,531	$	60,143	$	(4,253	)	$	55,890

In-process research and development (IPR&D)	$	8,669	$	—		$	8,669	$	9,685	$	—		$	9,685

Total intangible assets	$	65,337	$	(7,137	)	$	58,200	$	69,828	$	(4,253	)	$	65,575

Movements in intangible assets were due to the following:


	Product licensing rights			Product development rights			Purchased product rights and other			IPR&D
December 31, 2014	$	1,829		$	4,191		$	49,870		$	9,685
Purchase of product rights		100			1,568			3,000			—
Amortization of product rights		(296	)		(1,259	)		(3,178	)		—
Foreign currency movements and other		—			—			(6,294	)		(1,016	)

September 30, 2015	$	1,633		$	4,500		$	43,398		$	8,669

The weighted-average period prior to the next extension or renewal for the 22 products comprising our product licensing rights intangible asset was 55 months at September 30, 2015.

Note 8. Investment in Sagent Agila:

Changes in our investment in Sagent Agila during the nine months ended September 30, 2015 were as follows:


Investment in Sagent Agila at December 31, 2014	$	4,539
Equity in net income of Sagent Agila		1,510

Investment in Sagent Agila at September 30, 2015	$	6,049

Condensed statement of operations information of Sagent Agila is presented below.


	Three months ended September 30,				Nine months ended September 30,
Condensed statement of operations information	2015		2014		2015		2014
Net revenues	$	2,169	$	1,516	$	6,090	$	6,249
Gross profit		665		1,473		3,020		4,992
Net income		665		1,473		3,020		4,952

Note 9. Debt:

Credit facilities acquired in connection with the Omega acquisition

In connection with the acquisition of Omega on October 1, 2014, we assumed a series of credit facilities and mortgages with the National Bank of Canada (“NBC”) and the Business Development Bank of Canada (“BDC”), as described below.

Omega had an authorized credit facility (the “Omega operating credit facility”) in the amount of C$8,200 ($7,309) with the NBC. The Omega operating credit facility could be utilized in the form of floating-rate advances for an amount not exceeding C$7,000 ($6,239 as of the acquisition date) and advances in the form of letters of guarantee or letters of credit, within that limit for an amount not exceeding C$2,000 ($1,782 as of the acquisition date). The Omega operating credit facility could also be utilized in the form of advances to cover Omega’s currency risk for an amount not to exceed C$1,200 ($1,070 as of the acquisition date). On October 1, 2014, the Omega operating credit facility had floating-rate advances in the amount of C$1,530 ($1,364) bearing interest at the lender’s prime rate plus 0.50% (or an effective rate of 3.5%), which we assumed as part of the acquisition. As of December 31, 2014, C$3,272 ($2,824) was outstanding under the Omega operating credit facility.

In July 2014, Omega obtained a C$3,000 demand loan (the “Omega demand loan”), from the NBC bearing interest at the prime rate of the lender, plus a premium of 1.75% (effective rate 4.75%). The Omega demand loan was secured by all of the assets of Omega for C$3,000 plus an additional security interest of 20% of this amount, bearing interest at 4.75% per annum and matured in November 2014. We assumed the Omega demand loan ($2,674 as of the acquisition date) in connection with the acquisition and subsequently extended the maturity date to January 2015. The Omega operating credit facility and the Omega demand loan were secured by a first ranking security interest in the amount of C$8,250 ($7,354 as of the acquisition date) in Omega’s inventories, trade receivables and on the intellectual property of Omega, present and future. As of December 31, 2014, C$3,000 ($2,674) was outstanding under the Omega demand loan.

Omega also had C$267 ($238) outstanding on a decreasing revolving credit facility with the NBC (the “Omega decreasing revolving credit facility”) bearing interest at the prime rate of the lender, plus 1.0% (or an effective rate equal to 4.0%). The Omega decreasing revolving credit facility was secured by a first ranking security interest of C$1,000 ($891 as of the acquisition date) on the equipment, tooling and office furniture financed by the credit facility.

The Omega credit facilities were subject to certain restrictions, including the obligation to maintain certain financial ratios. As of October 1, 2014, Omega had not met certain of these financial ratios. As a result, the Omega decreasing revolving credit facility was classified as a current liability as of the acquisition date. In January 2015, we paid off all amounts outstanding under the Omega operating credit facility, the Omega demand loan and the Omega decreasing revolving credit facility with available cash on hand.

In addition to the above, Omega has five mortgage loans with the BDC (collectively the “Omega mortgages”) which we assumed in connection with the acquisition. The Omega mortgages, which require monthly installments and which are secured by specific Omega buildings and equipment, range in amount from C$70 to C$1,250 ($62 to $1,114 as of the acquisition date) and bear interest at the lender’s prime rate (5% as of the acquisition date) plus a premium ranging from 0%—1.5%. The Omega mortgages mature at various times from August 2019 through November 2036.

JPMorgan Chase Revolving Credit Loan Facility

On October 31, 2014, we entered into a credit agreement (the “Chase Agreement”) with JPMorgan Chase Bank, N.A., (“Chase”). As of September 30, 2015 and December 31, 2014, respectively, no borrowings were outstanding under the Chase Agreement and we were in compliance with all of our covenants under the Chase Agreement.

JP Morgan Chase China Fixed Assets Committed Loan Facility

On April 6, 2015, our subsidiary, Sagent (China) Pharmaceuticals, Co., Ltd. (“SCP”) entered into a fixed assets committed loan facility (“China Facility”) with JPMorgan Chase Bank (China) Company Limited, Shanghai Branch (“Chase China”). SCP may make drawings under the China Facility in an aggregate amount up to $18.0 million to finance capital expenditures relating to a production line expansion. Amounts drawn under the China Facility bear

interest at the LIBOR rate (or Chase China’s cost of funds if the long term foreign debt quota of Chase China is not available) plus 3.25%. Amounts drawn under the China Facility will be subject to an amortization schedule. Principal payments for any amounts drawn will be repaid in accordance with that schedule, between 36-60 months. As of September 30, 2015, no borrowings were outstanding under the Chase Agreement and we were in compliance with all of our covenants under the Chase Agreement.

In connection with the China Facility, on April 6, 2015 we and our wholly-owned subsidiary, Sagent Pharmaceuticals (“Sagent Wyoming”) entered into an amendment (the “Amendment”) to the Chase Agreement as well as a guaranty (the “Guaranty”) in favor of Chase and certain of its affiliates. Under the Guaranty and Amendment, the Company and Sagent Wyoming provide Chase and its affiliates a guaranty of obligations incurred by SCP under the China Facility.

Note 10. Accrued liabilities:

Accrued liabilities at September 30, 2015 and December 31, 2014 were as follows:


	September 30, 2015		December 31, 2014
Payroll and employee benefits	$	5,458	$	9,329
Sales and marketing		6,425		6,964
Taxes payable		1,201		1,040
Other accrued liabilities		2,029		2,013

	$	15,113	$	19,346

Note 11. Fair value measurements:

Assets measured at fair value on a recurring basis as of September 30, 2015 consisted of the following:


	Total fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Money market funds	$	19,859	$	19,859	$	—	$	—

Corporate bonds and notes		20,160		—		20,160		—

Short-term investments	$	20,160	$	—	$	20,160	$	—

Total assets	$	40,019	$	19,859	$	20,160	$	—

Liabilities
Contingent purchase consideration	$	95	$	—	$	—	$	95

Assets measured at fair value on a recurring basis as of December 31, 2014 consisted of the following:


	Total fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Money market funds	$	13,139	$	13,139	$	—	$	—

Corporate bonds and notes		18,513		—		18,513		—
Commercial paper		—		—		—		—

Short-term investments	$	18,513	$	—	$	18,513	$	—

Total assets	$	31,652	$	13,139	$	18,513	$	—

Liabilities
Contingent purchase consideration	$	605	$	—	$	—	$	605

The fair value of our Level 2 investments is based on a combination of quoted market prices of similar securities and matrix pricing provided by third-party pricing services utilizing securities of similar quality and maturity. The fair value of our Level 3 contingent consideration is based upon a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the product approval date.

There were no transfers of assets between Level 1, Level 2 or Level 3 during the periods presented.

We estimated the fair value of the contingent consideration to be $605 using a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the Cisatracurium product approval date.

The Changes in the fair value of our contingent purchase consideration measured using significant unobservable inputs (Level 3), during the nine months ending September 30, 2015 were as follows:


Balance at January 1, 2015	$	605
Issuance of contingent purchase consideration		—
Change in fair value of contingent purchase consideration		(510	)
Payment of contingent purchase consideration		—

Balance at September 30, 2015	$	95

The change in fair value of our contingent purchase consideration was recognized within selling, general and administrative expense in the Condensed Consolidated Statement of Operations.

Note 12. Accumulated other comprehensive income (loss):

Accumulated other comprehensive income (loss) at September 30, 2015 and December 31, 2014 is comprised of the following:


	September 30, 2015			December 31, 2014
Currency translation adjustment, net of tax	$	(14,615	)	$	(3,334	)
Unrealized gains (losses) on available for sale securities, net of tax		(10	)		(40	)

Total accumulated other comprehensive income (loss)	$	(14,625	)	$	(3,374	)

There were no amounts reclassified from accumulated other comprehensive income (loss) during the nine months ended September 30, 2015.

Note 13. Earnings per share

Basic earnings per share is calculated by dividing net income available to common stockholders by the weighted average number of common shares outstanding for the period. Because of their anti-dilutive effect, the following common share equivalents, comprised of restricted stock and unexercised stock options, have been excluded from the calculation of diluted earnings per share for the three and nine month periods ended September 30, 2015 and 2014, respectively:

Three months ended
September 30,

Nine months ended
September 30,

2015

2014

2015

2014

Anti-dilutive shares (in thousands)

2,188

435

2,188

1,124

The table below presents the computation of basic and diluted earnings per share for the three and nine months ended September 30, 2015 and 2014:


	Three months ended September 30,					Nine months ended September 30,
	2015			2014		2015			2014
Basic and dilutive numerator:
Net income (loss), as reported	$	(1,795	)	$	1,926	$	(3,945	)	$	10,114

Denominator:
Weighted-average common shares outstanding—basic (in thousands)		32,747			31,895		32,321			31,861
Net effect of dilutive securities:
Stock options and restricted stock		—			1,065		—			887

Weighted-average common shares outstanding—diluted (in thousands)		32,747			32,960		32,321			32,748

Net income (loss) per common share (basic)	$	(0.05	)	$	0.06	$	(0.12	)	$	0.32

Net income (loss) per common share (diluted)	$	(0.05	)	$	0.06	$	(0.12	)	$	0.31

Note 14. Stock-based compensation:

The following tables set forth stock option and restricted stock activity for the nine months ended September 30, 2015:


	Number of Shares
	Stock options			Restricted stock
Outstanding at December 31, 2014		2,543,362			128,209
Granted		411,743			140,971
Exercised		(779,505	)		(40,496	)
Forfeited		(168,166	)		(48,476	)

Outstanding at September 30, 2015		2,007,434			180,208

The aggregate intrinsic value of stock options exercised during the three months ended September 30, 2015 and 2014, was $1,524 and $319, respectively. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2015 and 2014, was $9,038 and $1,522, respectively.

Note 15. Net revenue by product:

Net revenue by therapeutic class is as follows:


	Three months ended September 30,				Nine months ended September 30,
Therapeutic class:	2015		2014		2015		2014
Anti-infective	$	31,891	$	21,370	$	96,453	$	74,896
Critical care		29,271		21,530		85,962		62,153
Oncology		14,037		22,459		52,773		68,373

	$	75,199	$	65,359	$	235,188	$	205,422

Note 16. Related party transactions:

As of September 30, 2015 and December 31, 2014, respectively, we had a receivable of $2,664 and $2,156 from Sagent Agila LLC, which is expected to offset future profit-sharing payments. As of September 30, 2015 and December 31, 2014, respectively, we had a payable of $11,573 and $8,079 to Sagent Agila LLC, principally for the acquisition of inventory and amounts due under profit-sharing arrangements.

Note 17. Income Taxes:

Our provision for income taxes for the three month ended September 30, 2015 and September 30, 2014 was $1,663 and $1,387, respectively. Our provision for income taxes for the nine months ended September 30, 2015 and September 30, 2014 was $3,813 and $2,774, respectively. As we have recorded a full valuation allowance against our Chinese deferred tax assets, we have not recorded a tax benefit for losses associated with SCP.

Note 18. Commitments and contingencies:

Litigation

From time to time, we are subject to claims and litigation arising in the ordinary course of business. These claims may include assertions that our products infringe existing patents and claims that the use of our products has caused personal injuries. We intend to vigorously defend any such litigation that may arise under all defenses that would be available to us.

Zoledronic Acid (Generic versions of Zometa ^® and Reclast ^®). On February 20, 2013, Novartis Pharmaceuticals Corporation (“Novartis”) sued the Company and several other defendants in the United States District Court for the District of New Jersey, alleging, among other things, that sales of the Company’s (i) zoledronic acid product under FDA NDA No. 203231, made by ACS Dobfar Info S.A. (“Info”), also a defendant, a generic bioequivalent version of Novartis’ Zometa ^® Ready-to-Use product, would infringe U.S. Patent No. 7,932,241 (the “241 Patent”) and U.S. Patent No. 8,324,189 (the “189 Patent”) and (ii) zoledronic acid product under FDA ANDA No. 202828, also made by Info, a generic version of Novartis’ Reclast ^® product, would infringe U.S. Patent No. 8,052,987 (the “987 Patent”) and the 241 Patent, and (iii) zoledronic acid product under FDA ANDA No. 202472, made by Actavis LLC, also a defendant, a generic version of Novartis’ Zometa ^® Pre Concentrate product, would infringe the 189 Patent. (In Re: Certain Consolidated Zoledronic Acid Cases; Consolidated Civil Action No. 12-03967(SDW)(SCM) [Consolidated with Civil Action Nos. 12-cv-04393, 13-cv-01028, 13-cv-02379, 13-cv-4669, 13-cv-5125, 13-cv-6835, 13-cv-7914 and 14-cv-18411]). On March 1, 2013, the District Court denied Novartis’ request for a temporary restraining order against the Company and the other defendants, including Actavis and Info. On March 6, 2013 the Company, began selling Actavis’ zoledronic acid vial, the generic version of Zometa. Also, as of August 27, 2013 and October 1, 2013, the Company began selling zoledronic acid premix bags in 4mg/100ml and 5mg/100ml presentations, respectively. On December 3, 2014, Novartis sued the Company, alleging, among other things, that sales of the Company’s zoledronic acid product under FDA ANDA No. 091493, made by Hameln RDS GMBH, a generic version of Novartis’ Zometa ^® Pre-concentrate product, would infringe the 189 Patent. (Novartis Pharmaceuticals Corporation v. Sagent Pharmaceuticals, Inc. et. al., Case No. 2:14-cv-07556(SDW)(SCM) and together with the Consolidated Civil Action Case No. 13-cv-1028, the “Litigation”).

On October 13, 2015, the Company and Novartis agreed to settle the Litigation. Pursuant to the terms of the settlement, we will pay Novartis $5,000 in exchange for a release of claims associated with the 241, 987 and 189 Patents pertaining to the following regulatory submissions: FDA NDA No. 203231, FDA ANDA No. 202828, FDA

ANDA No. 202472 and FDA ANDA No. 091493 (collectively the “Regulatory Submissions”), and acquire a license to sell the zoledronic acid products as approved by their Regulatory Submissions (excluding sales of product manufactured under FDA ANDA No.202472 after December 31, 2014) in the United States. The settlement is subject to confirmation by the US Federal Trade Commission. Concurrent with the Novartis settlement, we are entitled to receive $1,477 from Info and Actavis, representing their collective share of the $5,000.

We have determined that $1,683 of the settlement represents a future license to sell the zoledronic acid products. This amount has been recorded within Other assets on the Condensed Consolidated Balance Sheet as of September 30, 2015, offset by the portion of the Info reimbursement, $607, related to the license period. The remaining net settlement amount of $2,447 owed to Novartis has been recorded as Legal settlement within the Condensed Consolidated Statement of Operations for the three and nine months ended September 30, 2015.

At this time, there are no other proceedings of which we are aware that are considered likely to have a material adverse effect on the consolidated financial position or results of operations.

Note 19. Management transition costs:

In March 2015, we completed a management transition following the retirement of our founder and Chief Executive Officer and resignation of our President. In June 2015, we eliminated certain positions in the US as part of the ongoing review of our business. In the third quarter of 2015, we incurred additional costs, primarily related to the onboarding of our new Chief Executive Officer. Costs associated with these matters, primarily severance related charges and costs associated with recruiting and retaining a new CEO, were all incurred in the Sagent US operating segment, and are reflected in the management transition caption in the consolidated statement of operations for the three and nine months ended September 30, 2015. Of the charges, $189 and $3,310 were paid during the three and nine months ended September 30, 2015, respectively. Total costs accrued within the Accounts Payable and Accrued liabilities captions of the balance sheet at September 30, 2015 were $307 and $958, respectively.

Note 20. Geographic and segment information

Management uses segment information to evaluate segment performance and allocate resources. Historically we have operated in a single reportable segment, the United States. Effective October 1, 2014, in connection with the Omega acquisition, we began operating in two reportable segments comprised of operations organized geographically within the United States (Sagent US segment) and Canada (Omega segment), each of which develop, source, manufacture and market generic injectable products for sale within the their respective countries. Each segment derives a significant portion of its revenues from a single class of pharmaceutical wholesale customers within that country. Management utilizes segment operating income as its measure of segment profitability.

Segment and geographic data for the three and nine months ended September 30, 2015 includes the impact of Omega. Shared costs for certain corporate functions, including but not limited to, corporate finance and legal, are included within the Sagent US segment profitability that management reviews.

Geographic and segment data is as follows:


	Three months ended September 30,						Nine months ended September 30,
Segment revenues:	2015			2014			2015			2014
United States	$	67,648		$	65,359		$	211,623		$	205,395
Others		226			—			738			27

Sagent US segment		67,874			65,359			212,361			205,422

Canada (Omega segment)		7,325			—			22,827			—

Total net revenue	$	75,199		$	65,359		$	235,188		$	205,422

Income (loss) before income taxes
Sagent US	$	1,391		$	4,044		$	2,885		$	13,994
Canada (Omega segment)		351			—			(142	)		—

Total segment operating income		1,742			4,044			2,743			13,994
Interest income and other		(1,686	)		(536	)		(2,225	)		(465	)
Interest expense		(188	)		(195	)		(650	)		(641	)

Income (loss) before income taxes	$	(132	)	$	3,313		$	(132	)	$	12,888


	September 30,
	2015		2014
Segment assets:
United States	$	206,802	$	249,953
China		57,742		66,612

Sagent US segment		264,544		316,565
Canada (Omega segment)		95,065		—

Total assets	$	359,609	$	316,565

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our condensed consolidated financial statements included elsewhere in this report and with our audited financial statements and the notes found in our most recent Annual Report on Form 10-K filed with the SEC on March 16, 2015. Unless otherwise noted, all dollar amounts are in thousands.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “could have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies, our product pipeline and anticipated product approvals or the expected outcome or impact of pending or threatened litigation are forward-looking statements. In addition, this report contains forward-looking statements regarding the adequacy of our current cash balances to fund our ongoing operations; our utilization of our net operating loss carryforwards; our ability to realize the expected benefits from our acquisition of Omega; our ability to realize the expected benefits from our acquisition of and investment in our China subsidiary; and the additional investments required to be made in our China subsidiary to achieve its manufacturing potential.

The forward-looking statements contained in this Quarterly Report on Form 10-Q are subject to a number of risks and uncertainties, and the cautionary statements set forth below, as well as elsewhere in this Quarterly Report on Form 10-Q, and those contained in Item 1A under the heading “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC on March 16, 2015, identify important factors that could cause actual results to differ materially from those indicated by our forward-looking statements. Such factors, include, but are not limited to:

•

we rely on our business partners for the manufacture of a significant portion of our products, and if our business partners fail to supply us with high-quality active pharmaceutical ingredient (“API”) or finished products in the quantities we require on a timely basis, sales of our products could be delayed or prevented, and our revenues and margins could decline, which could have a material adverse effect on our business, financial condition and results of operations;

•

if we or any of our business partners are unable to comply with the quality and regulatory standards applicable to pharmaceutical drug manufacturers, or if approvals of pending applications are not granted or are delayed, we may be unable to meet the demand for our products, may lose potential revenues and our business, financial position and results of operations could be materially adversely effected;

•

changes in the regulations, enforcement procedures or regulatory policies established by the FDA and other regulatory agencies could increase the costs or time of development of our products and could delay or prevent sales of our products and our revenues could decline and, as a result, our business, financial condition and results of operations could be materially adversely affected;

•

two of our products, heparin and levofloxacin in premix bags, represent a significant portion of our net revenue. Each of these products is manufactured by and supplied to us by a single vendor, and, if the volume or pricing of either of these products declines, or we are unable to satisfy market demand for either of these products, such event could have a material adverse effect on our business, financial position and results of operations;

•

we participate in highly competitive markets, dominated by a few large competitors, and if we are unable to compete successfully, our revenues could decline and our business, financial condition and results of operations could be materially adversely affected;

•

if we are unable to continue to develop and commercialize new products in a timely and cost-effective manner, we may not achieve our expected revenue growth and profitability, or our business, results of operations and financial position could be adversely affected;

•

if we are unable to maintain our group purchasing organizations (“GPO”) and distributor relationships, our revenues could decline and our results of operations could be adversely affected;

•

we rely on a limited number of pharmaceutical wholesalers to distribute our products;

•

we depend to a significant degree upon our key personnel, the loss of whom could adversely affect our operations;

•

if we fail to attract and retain the talent required for our business, our business could be materially harmed;

•

our inability to manage our planned growth or successfully integrate newly acquired businesses could harm our business;

•

we may be exposed to product liability claims that could cause us to incur significant costs or cease selling some of our products;

•

our products may infringe the intellectual property rights of third parties, and in such cases we may incur substantial liabilities and may be unable to commercialize products in a profitable manner or at all;

•

healthcare reform legislation or other policy changes may adversely affect our business;

•

our business could suffer if reimbursement by government-sponsored or private sector insurance programs for our current or future products is reduced or modified;

•

we may need to raise additional capital in the event we change our business plan or encounter unexpected developments, which may cause dilution to our existing stockholders or restrict or limit our operations;

•

we are subject to risks associated with managing our international network of business relationships, which include business partners and other suppliers of components, API and finished products located throughout the world;

•

we may never realize the expected benefits from our manufacturing facility in China and it will require substantial capital resources to reach its manufacturing potential and achieve overall profitability;

•

we may never realize the expected benefits from our acquisition of Omega and it will require substantial capital resources to maintain its manufacturing capabilities and overall profitability;

•

we rely on a single vendor to manage our order to cash cycle and our distribution activities in the U.S. and the loss or disruption of service from this vendor could adversely affect our operations and financial condition;

•

we are likely to incur substantial costs associated with both implementation and maintenance of our new enterprise resource planning software and other related applications, and unforeseen problems may arise with the implementation. If the new systems do not perform as originally planned, our business, financial position and results of operations could be adversely affected;

•

currency fluctuations may have an adverse effect on our business; and

•

we may seek to engage in strategic transactions, including the acquisition of products or businesses, that could have a variety of negative consequences, and we may not realize the intended benefits of such transactions.

We derive many of our forward-looking statements from our work in preparing, reviewing and evaluating our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, it is impossible for us to anticipate or accurately calculate the impact of all factors that could affect our actual results. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation and do not intend to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Introduction

We are a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which we sell primarily throughout North America through our two operating segments. Initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, we reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with our initial public offering, on April 26, 2011.

With a primary focus on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, we offer our customers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. We generally seek to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. Our management team includes industry veterans who have served critical functions at other injectable pharmaceutical companies or key customer groups and have long-standing relationships with customers, regulatory agencies, and suppliers. We have rapidly established a growing and diverse product portfolio and product pipeline as a result of our innovative business model. Our model combines an extensive network of international development, sourcing and manufacturing collaborations with our proven and experienced regulatory, quality assurance, business development, project management, and sales and marketing teams.

On June 4, 2013, we acquired the remaining 50% equity interest in Kanghong Sagent (Chengdu) Pharmaceutical Co. Ltd. (“KSCP”) from our former joint venture partner (the “SCP Acquisition”). In August 2013, we formally changed the name of this entity to Sagent (China) Pharmaceuticals Co., Ltd. (“SCP”). The SCP facility, which received its Establishment Inspection Report from the FDA in April 2013, and first product approval in June 2013, provides us with the ability to develop and manufacture a portion of our product portfolio. In August 2015, we announced that we are evaluating strategic alternatives to optimize the value of the SCP facility, including its potential sale.

On October 1, 2014, we, through our wholly-owned subsidiary, Sagent Acquisition Corp., a Canadian company, acquired all of the issued and outstanding shares of the capital stock of 7685947 Canada Inc., and its subsidiary, Omega Laboratories Limited (collectively, “Omega”), a privately held Canadian pharmaceutical and specialty healthcare products company. Omega represents our first international market expansion, and the facility currently provides us with the ability to manufacture products for the Canadian and other international markets.

Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States (“GAAP”).

Adjusted Gross Profit

We use the non-GAAP financial measure “Adjusted Gross Profit” and corresponding ratios. We define Adjusted Gross Profit as gross profit plus our share of the gross profit earned through our Sagent Agila joint venture which is included in the Equity in net (income) loss of joint ventures line on the consolidated statements of operations and the impact of product-related non-cash charges arising from business combinations. We believe that Adjusted Gross Profit is relevant and useful supplemental information for our investors. Our management believes that the presentation of this non-GAAP financial measure, when considered together with our GAAP financial measures and the reconciliation to the most directly comparable GAAP financial measure, provides a more complete understanding of the factors and trends affecting Sagent than could be obtained absent these disclosures. Management uses Adjusted Gross Profit and corresponding ratios to make operating and strategic decisions and evaluate our performance. We have disclosed this non-GAAP financial measure so that our investors have the same financial data that management uses with the intention of assisting you in making comparisons to our historical operating results and analyzing our underlying performance. Our management believes that Adjusted Gross Profit provides a useful supplemental tool to consistently evaluate the profitability of our products that have profit sharing arrangements. The limitation of this measure is that it includes an item that does not have an impact on gross profit reported in accordance with GAAP. The best way that this limitation can be addressed is by using Adjusted Gross Profit in combination with our GAAP reported gross profit. Because Adjusted Gross Profit calculations may vary among other companies, the Adjusted Gross Profit figures presented below may not be comparable to similarly titled measures used by other companies. Our use of Adjusted Gross Profit is not meant to and should not be considered in isolation or as a substitute for, or superior to, any GAAP financial measure. You should carefully evaluate the following tables reconciling Adjusted Gross Profit to our GAAP reported gross profit for the periods presented (dollars in thousands).


	Three months ended September 30,										% of net revenue, three months ended September 30,
	2015		2014		$ Change			% Change			2015			2014			% Change
Adjusted Gross Profit	$	24,695	$	19,507	$	5,188			27	%		32.8	%		29.8	%		3.0	%
Sagent portion of gross profit earned by Sagent Agila joint venture		333		737		(404	)		-55	%		0.4	%		1.1	%		-0.7	%
Product-related non-cash charges arising from business combinations		—		—		—			n/m			0.0	%		0.0	%		0.0	%

Gross Profit	$	24,362	$	18,770	$	5,592			30	%		32.4	%		28.7	%		3.7	%


	Nine months ended September 30,										% of net revenue, nine months ended September 30,
	2015		2014		$ Change			% Change			2015			2014			% Change
Adjusted Gross Profit	$	66,877	$	64,242	$	2,635			4	%		28.4	%		31.3	%		-2.9	%
Sagent portion of gross profit earned by Sagent Agila joint venture		1,510		2,496		(986	)		-40	%		0.6	%		1.2	%		-0.6	%
Product-related non-cash charges arising from business combinations		640		—		640			n/m			0.3	%		0.0	%		0.3	%

Gross Profit	$	64,727	$	61,746	$	2,981			5	%		27.5	%		30.1	%		-2.6	%

EBITDA and Adjusted EBITDA

We use the non-GAAP financial measures “EBITDA” and “Adjusted EBITDA” and corresponding growth ratios. We define EBITDA as net income (loss) less interest expense, net of interest income, provision for income taxes, depreciation and amortization. We define Adjusted EBITDA as net income (loss) less interest expense, net of interest income, provision for income taxes, depreciation and amortization, stock-based compensation expense, management transition related costs, acquisition-related costs, the impact of unrealized foreign currency gains or losses, and the impact of product-related non-cash charges arising from business combinations. We believe that EBITDA and Adjusted EBITDA are relevant and useful supplemental information for our investors. Our management believes that the presentation of these non-GAAP financial measures, when considered together with our GAAP financial measures and the reconciliation to the most directly comparable GAAP financial measures, provides a more complete understanding of the factors and trends affecting Sagent than could be obtained absent these disclosures. Management uses EBITDA, Adjusted EBITDA and corresponding ratios to make operating and strategic decisions and evaluate our performance. We have disclosed these non-GAAP financial measures so that our investors have the same financial data that management uses with the intention of assisting you in making comparisons to our historical operating results and analyzing our underlying performance. Our management believes that EBITDA and Adjusted EBITDA are useful supplemental tools to evaluate the underlying operating performance of the company on an ongoing basis. The limitation of these measures is that they exclude items that have an impact on net income (loss). The best way that these limitations can be addressed is by using EBITDA and Adjusted EBITDA in combination with our GAAP reported net income (loss). Because EBITDA and Adjusted EBITDA calculations may vary among other companies, the EBITDA and Adjusted EBITDA figures presented below may not be comparable to similarly titled measures used by other companies. Our use of EBITDA and Adjusted EBITDA is not meant to and should not be considered in isolation or as a substitute for, or superior to, any GAAP financial measure. You should carefully evaluate the following tables reconciling EBITDA and Adjusted EBITDA to our GAAP reported net income (loss) for the periods presented (dollars in thousands).


	Three months ended September 30,
	2015			2014		$ Change			% Change
Adjusted EBITDA	$	8,789		$	7,248	$	1,541			21	%
Stock-based compensation expense		921			1,203		(282	)		-23	%
Management transition costs		645			—		645			n/m
Acquisition-related costs		535			872		(337	)		-39	%
Unrealized foreign exchange losses²		1,560			—		1,560			n/m
Legal settlement		2,447			—		2,447			n/m

EBITDA	$	2,681		$	5,173	$	(2,492	)		-48	%

Depreciation and amortization expense¹		2,655			1,773		882			50	%
Interest expense, net		158			87		71			82	%
Provision for income taxes		1,663			1,387		276			20	%

Net income (loss)	$	(1,795	)	$	1,926	$	(3,721	)		n/m


	Nine months ended September 30,
	2015			2014		$ Change			% Change
Adjusted EBITDA	$	24,058		$	23,956	$	102			0.4	%
Stock-based compensation expense		2,845			3,657		(812	)		-22	%
Management transition costs		4,647			—		4,647			n/m
Acquisition-related costs		1,856			872		984			113	%
Unrealized foreign exchange losses²		2,440			—		2,440			n/m
Product-related non-cash charges arising from business combinations		640			—		640			n/m
Legal settlement		2,447			—		2,447			n/m

EBITDA	$	9,183		$	19,427	$	(10,244	)		-53	%

Depreciation and amortization expense¹		8,746			6,237		2,509			40	%
Interest expense, net		569			302		267			88	%
Provision for income taxes		3,813			2,774		1,039			37	%

Net income (loss)	$	(3,945	)	$	10,114	$	(14,059	)		n/m

¹Amortization expense excludes $17 and $23 of amortization in the three months ended September 30, 2015 and 2014, respectively, and $50 and $70 of amortization in the nine months ended September 30, 2015 and 2014, respectively, related to deferred financing fees, which is included within interest expense and other in our Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014.

²Unrealized foreign exchange losses reflect the impact of foreign currency movements on intercompany loans, primarily related to the devaluation of the Canadian dollar relative to the US dollar, and are included in Interest income and other income (expense), net, in our Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014.

Discussion and Analysis

Consolidated results of operations

The following compares our consolidated results of operations for the three months ended September 30, 2015 with those of the three months ended September 30, 2014:


	Three months ended September 30,
	2015			2014			$ change			% change
Net revenue	$	75,199		$	65,359		$	9,840			15	%
Cost of sales		50,837			46,589			4,248			9	%

Gross profit		24,362			18,770			5,592			30	%
Gross profit as % of net revenue		32.4	%		28.7	%		3.7	%

Operating expenses:
Product development		7,923			3,677			4,246			116	%
Selling, general and administrative		11,403			10,914			489			4	%
Acquisition-related costs		535			872			(337	)		-39	%
Management transition costs		645			—			645			n/m
Equity in net income of joint ventures		(333	)		(737	)		(404	)		-55	%

Total operating expenses		20,173			14,726			5,447			37	%

Legal settlement		2,447			—			2,447			n/m
Income from operations		1,742			4,044			(2,302	)		-57	%
Interest income and other income (expense), net		(1,686	)		(536	)		(1,150	)		215	%
Interest expense		(188	)		(195	)		(7	)		-4	%


Income (loss) before income taxes		(132	)		3,313			(3,445	)		n/m
Provision for income taxes		1,663			1,387			276			20	%

Net income (loss)	$	(1,795	)	$	1,926		$	(3,721	)		n/m


Net income (loss) per common share:
Basic	$	(0.05	)	$	0.06		$	(0.11	)		n/m
Diluted	$	(0.05	)	$	0.06		$	(0.11	)		n/m

Net revenue: Net revenue for the three months ended September 30, 2015 totaled $75.2 million, inclusive of $7.3 million of net revenue from our Omega segment, an increase of $9.8 million, or 15%, as compared to $65.4 million for the three months ended September 30, 2014. The launch of eight new codes or presentations of four products since September 30, 2014 contributed $2.7 million of the net revenue increase in the third quarter of 2015. Net revenue for products launched prior to September 30, 2014 decreased $0.5 million, or 1%, to $64.8 million in the third quarter of 2015.

Cost of sales: Cost of goods sold for the three months ended September 30, 2015 totaled $50.8 million, inclusive of $5.0 million of cost of sales incurred in our Omega segment, an increase of $4.2 million, or 9%, as compared to $46.6 million for the three months ended September 30, 2014. Gross profit as a percentage of net revenues was 32.4% for the three months ended September 30, 2015 compared to 28.7% for the three months ended September 30, 2014. Adjusted Gross Profit as a percentage of net revenue was 32.8% for the three months ended September 30, 2015 compared to 29.8% for the three months ended September 30, 2014. The increase in gross profit as a percentage of net revenue is primarily due to improved product mix and the benefit of $0.7 million from the receipt of payment from certain manufacturing partners for the settlement of certain supply issues.

Product development: Product development expense for the three months ended September 30, 2015 totaled $7.9 million, inclusive of $0.7 million of product development costs incurred in our Omega segment, an increase of $4.2 million, or 116%, as compared to $3.7 million for the three months ended September 30, 2014. The increase in product development expense was primarily due to higher milestone expenses for products in our development pipeline in 2015.

As of September 30, 2015, our new product pipeline included 42 products represented by 68 ANDAs which we had filed, or licensed rights to, that were under review by the FDA and three products represented by eight ANDAs that have been recently approved and were pending commercial launch. We also had an additional 21 products represented by 27 ANDAs under initial development at September 30, 2015.

Selling, general and administrative: Selling, general and administrative expenses for the three months ended September 30, 2015, totaled $11.4 million, inclusive of $1.2 million of costs incurred in our Omega segment, an increase of $0.5 million, or 4%, as compared to $10.9 million for the three months ended September 30, 2014. Selling, general and administrative expense as a percentage of net revenue was 15% and 17% for the three months ended September 30, 2015 and 2014, respectively.

Acquisition-related costs: Acquisition-related costs for the three months ended September 30, 2015 totaled $0.5 million, a decrease of $0.3 million, or 39%, as compared to $0.9 million for the three months ended September 30, 2014. Acquisition-related costs in the three months ended September 30, 2014 were associated with the acquisition of Omega.

Management transition costs: Management transition costs for the three months ended September 30, 2015 totaled $0.6 million, primarily related to our transition to a new Chief Executive Officer. No management transition costs were incurred in the three months ended September 30, 2014.

Equity in net income of joint ventures: Equity in net income of joint ventures for the three months ended September 30, 2015 totaled $0.3 million, a decrease of $0.4 million as compared to $0.7 million for the three months ended September 30, 2014. The change is related to a decline in sales of Sagent Agila products during the three months ended September 30, 2015, primarily due to the ongoing manufacturing issues at Sagent Agila’s SFF facility, which has been subject to a warning letter since September 2013.

Legal settlement: Legal settlement of $2.4 million for the three months ended September 30, 2015 represents the $5.0 million settlement of our outstanding patent infringement lawsuit with Novartis Pharmaceuticals Corporation (“Novartis”), net of $1.5 million of recoveries from our manufacturing partners associated with the settlement and $1.1 million allocated to acquired product licensing rights.

Interest income and other income (expense), net: Interest income and other income (expense), net for the three months ended September 30, 2015 totaled $1.7 million of expense, as compared to $0.5 million of expense in the three months ended September 30, 2014. The increase was predominately related to $1.6 million of unrealized foreign currency losses resulting from the weakening of the Canadian dollar and Chinese Renminbi.

Interest expense: Interest expense for the three months ended September 30, 2015 and September 30, 2014 totaled $0.2 million.

Provision for income taxes: Our provision for income taxes for the three months ended September 30, 2015 was $1.7 million, an increase of $0.3 million as compared to $1.4 million in the three months ended September 30, 2014. As we have recorded a full valuation allowance against our Chinese deferred tax assets, we have not recorded a tax benefit for losses associated with SCP.

Net income (loss) and diluted net earnings (loss) per common share: The net loss for the three months ended September 30, 2015 was $1.8 million, as compared to net income of $1.9 million for the three months ended September 30, 2014. Diluted net earnings (loss) per common share decreased by $0.11. The decrease in diluted net earnings (loss) per common share is due to the following factors:


Diluted EPS for the three months ended September 30, 2014	$	0.06
Decrease in earnings		(0.11	)
Decrease in common shares outstanding		—

Diluted EPS for the three months ended September 30, 2015	$	(0.05	)

The following compares our consolidated results of operations for the nine months ended September 30, 2015 with those of the nine months ended September 30, 2014:


	Nine months ended September 30,
	2015			2014			$ change			% change
Net revenue	$	235,188		$	205,422		$	29,766			14	%
Cost of sales		170,461			143,676			26,785			19	%

Gross profit		64,727			61,746			2,981			5	%
Gross profit as % of net revenue		27.5	%		30.1	%		-2.6	%

Operating expenses:
Product development		18,658			17,734			924			5	%
Selling, general and administrative		35,886			31,622			4,264			13	%
Acquisition-related costs		1,856			872			984			113	%
Management transition costs		4,647			—			4,647			n/m
Equity in net income of joint ventures		(1,510	)		(2,476	)		(966	)		-39	%

Total operating expenses		59,537			47,752			11,785			25	%

Legal Settlement		2,447			—			2,447			n/m

Income from operations		2,743			13,994			(11,251	)		-80	%

Interest income and other income (expense), net		(2,225	)		(465	)		(1,760	)		378	%

Interest expense		(650	)		(641	)		9			1	%


Income (loss) before income taxes		(132	)		12,888			(13,020	)		-101	%
Provision for income taxes		3,813			2,774			1,039			37	%


Net income (loss)	$	(3,945	)	$	10,114		$	(14,059	)		n/m


Net income (loss) per common share:
Basic	$	(0.12	)	$	0.32		$	(0.44	)		n/m
Diluted	$	(0.12	)	$	0.31		$	(0.43	)		n/m

Net revenue: Net revenue for the nine months ended September 30, 2015 totaled $235.2 million, inclusive of $22.8 million of net revenue from our Omega segment, an increase of $29.8 million, or 14%, as compared to $205.4 million for the nine months ended September 30, 2014. The launch of eight new codes or presentations of four products since September 30, 2014 contributed $5.1 million of the net revenue increase in the first nine months of 2015. Net revenue for products launched prior to September 30, 2014 increased $0.9 million, or less than 1%, to $206.5 million for the nine months ended September 30, 2015.

Cost of sales: Cost of goods sold for the nine months ended September 30, 2015 totaled $170.5 million, inclusive of $17.3 million of cost of sales incurred in our Omega segment, an increase of $26.8 million, or 19%, as compared to $143.7 million for the nine months ended September 30, 2014. Gross profit as a percentage of net revenues was 27.5% for the nine months ended September 30, 2015 compared to 30.1% for the nine months ended September 30, 2014. Adjusted Gross Profit as a percentage of net revenue was 28.4% for the nine months ended September 30, 2015, and 31.3% for the nine months ended September 30, 2014. The decrease in gross profit as a percentage of net revenue is primarily due to the loss of a key oncolytic product partially offset by the benefit of $0.7 million from the receipt of payment from certain manufacturing partners for the settlement of certain supply issues.

Product development: Product development expense for the nine months ended September 30, 2015 totaled $18.7 million, inclusive of $2.3 million of product development costs in our Omega segment, an increase of $0.9 million, or 5%, as compared to $17.7 million for the nine months ended September 30, 2014. The decrease in US product development expense was primarily due to lower milestone expenses for products in our development pipeline, and a $1.0 million credit due to a settlement payment following the renegotiation of a development contract.

Selling, general and administrative: Selling, general and administrative expenses for the nine months ended September 30, 2015, totaled $35.9 million, inclusive of $3.4 million of costs in our Omega segment, an increase of $4.3 million, or 13%, as compared to $31.6 million for the nine months ended September 30, 2014. The remaining increase in selling, general and administrative expense was primarily due to increased public company costs partially offset by lower employee related costs. Selling, general and administrative expense as a percentage of net revenue was 15% for the nine months ended September 30, 2015 and 2014.

Acquisition-related costs: Acquisition-related costs for the nine months ended September 30, 2015 totaled $1.9 million, an increase of $1.0 million, or 113%, as compared to $0.9 million for the nine months ended September 30, 2014.

Management transition costs: Management transition costs for the nine months ended September 30, 2015 totaled $4.6 million. The costs are primarily severance related charges following the retirement of our founder and Chief Executive Officer and resignation of our President in March 2015, severance charges related to the elimination of certain other positions in the US in June 2015 and transition costs associated with our new Chief Executive Officer in the third quarter of 2015. No management transition costs were incurred in the nine months ended September 30, 2014.

Equity in net income of joint ventures: Equity in net income of joint ventures for the nine months ended September 30, 2015 totaled $1.5 million, a decrease of $1.0 million as compared to $2.5 million for the nine months ended September 30, 2014, related to a decrease in sales of Sagent Agila products during the nine months ended September 30, 2015.

Legal settlement: Legal settlement of $2.4 million for the nine months ended September 30, 2015 represents the $5.0 million settlement of our outstanding patent infringement lawsuit with Novartis, net of $1.5 million of recoveries from our manufacturing partners associated with the settlement and $1.1 million of acquired product licensing rights.

Interest income and other income (expense), net: Interest income and other income (expense), net for the nine months ended September 30, 2015 totaled $2.2 million of expense, as compared to $0.5 million of expense in the nine months ended September 30, 2014. The increase in expense primarily relates to unrealized foreign exchange losses on intercompany financing, primarily related to the devaluation of the Canadian dollar versus the US dollar.

Interest expense: Interest expense for the nine months ended September 30, 2015 totaled $0.7 million of expense, an increase of less than $0.1 million, or 1%, as compared to $0.6 million of expense in the nine months ended September 30, 2014.

Provision for income taxes: Our provision for income taxes for the nine months ended September 30, 2015 was $3.8 million, an increase of $1.0 million as compared to $2.8 million in the nine months ended September 30, 2014. As we have recorded a full valuation allowance against our Chinese deferred tax assets, we have not recorded a tax benefit for losses associated with SCP.

Net income (loss) and diluted net earnings (loss) per common share: The net loss for the nine months ended September 30, 2015 was $3.9 million, as compared to net income of $10.1 million for the nine months ended September 30, 2014. Diluted net earnings (loss) per common share decreased by $0.43. The decrease in diluted net earnings (loss) per common share is due to the following factors:


Diluted EPS for the nine months ended September 30, 2014	$	0.31
Decrease in earnings		(0.43	)
Decrease in common shares outstanding		—

Diluted EPS for the nine months ended September 30, 2015	$	(0.12	)

Liquidity and Capital Resources

Our future capital requirements will depend on a number of factors, including the continued commercial success of our existing products, launching the products that have been recently approved and are pending commercial launch or are pending approval as of September 30, 2015, successfully identifying and sourcing other new product opportunities, manufacturing products at our wholly-owned Chinese manufacturing facility, capital expansion at our wholly-owned subsidiaries and further business development activity.

Based on our existing business plan, we expect that cash, cash equivalents and short-term investments, together with operating cash flows and borrowings available under our Chase revolving loan facility and our Chase China committed fixed assets facility, will be sufficient to fund our planned operations, the continued development of our product pipeline, investments in working capital, joint venture distributions and capital expansion at our Omega facility, for at least the next 12 months. However, we may require additional funds in the event that we change our business plan, pursue additional strategic transactions, including the acquisition of businesses or products, or encounter unexpected developments, including unforeseen competitive conditions within our product markets, changes in the general economic climate, changes in the regulatory environment, the loss of or negative developments affecting key relationships with suppliers, group purchasing organizations or end-user customers or other unexpected developments that may have a material effect on the cash flows or results of operations of our business.

To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings or debt financings, which may not be available to us on terms we consider acceptable or at all. Our ability to raise additional funding, if necessary, is subject to a variety of factors that we cannot predict with certainty, including our future results of operations, our relative levels of debt and equity, the volatility and overall condition of the capital markets and the market prices of our securities. Debt financing, if available, may only be available to us on less favorable terms than our existing Chase revolving loan facility, including higher interest rates or greater exposure to interest rate risk. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders.

If additional funding is not available, we may be required to terminate, significantly modify or delay the development or commercialization of new products and may not be able to achieve the manufacturing potential of our SCP facility or expansion of our Omega facility. We may elect to raise additional funds even before we need them if we believe that the conditions for raising capital are favorable.

Cash Flows

Overview

On September 30, 2015, cash, cash equivalents and short term investments totaled $46.0 million. Working capital totaled $115.0 million and our current ratio (current assets to current liabilities) was approximately 2.6 to 1.0.

Sources and Uses of Cash

Operating activities: Net cash used in operating activities was $12.9 million for the nine months ended September 30, 2015, compared with net cash provided by operating activities of $19.5 million during the nine months ended September 30, 2014. The reduction in cash provided by operations was primarily due to the increase in inventory in the nine months ended September 30, 2015 and the decline in our net income.

Investing activities: Net cash used in investing activities was $19.8 million for the nine months ended September 30, 2015, primarily related to the final installment payment for our acquisition of SCP, increased capital expenditures related to the new manufacturing line at our Omega facility and the net change in our short term investments. Net cash provided by investing activities of $84.5 million during the nine months ended September 30, 2014 primarily related to the net sale of short-term investments in anticipation of the October 1, 2014 acquisition of Omega, partially offset by increased capital expenditures and acquisition of product rights.

Financing activities: Net cash provided by financing activities was $3.6 million for the nine months ended September 30, 2015, primarily related to proceeds from stock option exercises, partially offset by the repayment of the then outstanding balance of our loans with the National Bank of Canada. Net cash used in financing activities for the nine months ended September 30, 2014 was $10.0 million, primarily related to repayment in full of the then outstanding balance of our ABC Loans.

Credit facilities

In February 2012, we repaid all of our outstanding borrowings and replaced our previous facilities with an asset based revolving loan facility with Silicon Valley Bank (“SVB”). In September 2013, we entered into a Second Loan Modification agreement with SVB, and subsequently, on October 31, 2014, we terminated our asset based revolving loan facility with SVB and replaced it with a new asset based revolving loan credit facility with JPMorgan Chase Bank, N.A. (“Chase”). In April 2015, SCP entered a fixed asset committed loan facility with JPMorgan Chase Bank (China) Company Limited, Shanghai Branch (“Chase China”).

In June 2013, SCP had two loan facilities with the Agricultural Bank of China (“ABC”) that existed prior to the SCP Acquisition. We repaid in full the amounts outstanding under these facilities in January 2014. In October 2014, Omega had a series of loan facilities that existed prior to the Omega acquisition. Refer below for a description of our facilities with Chase, Chase China, Omega’s facilities, and the SVB and ABC facilities which were terminated in 2014.

Asset based revolving credit loan facility

On October 31, 2014, we entered into a credit agreement with JPMorgan Chase Bank, N.A., (the “Chase Agreement”). The Chase Agreement provides for an $80.0 million asset based revolving credit loan facility, with availability subject to a borrowing base consisting of eligible cash, short-term investments, accounts receivable and inventory and the satisfaction of conditions precedent specified in the Chase Agreement. The Chase Agreement provides for an accordion feature, whereby we may increase the revolving commitment up to an additional $25.0 million subject to certain customary terms and conditions including pro forma compliance with a fixed charge coverage ratio (as defined in the Chase Agreement) of 1.00 to 1.00. The Chase Agreement matures on October 31, 2019, at which time all amounts outstanding will be due and payable. Borrowings under the Chase Agreement may be used for general corporate purposes, including funding working capital. Amounts drawn bear an interest rate equal to, at our option, either a Eurodollar rate plus 2.00% per annum or an alternative base rate plus 1.00% per annum. We also incur a commitment fee on undrawn amounts equal to 0.25% per annum.

The Chase Agreement is guaranteed by us at the time of closing and is secured by a lien on substantially all of our and our principal domestic subsidiary’s assets and any future domestic subsidiary guarantors’ assets. The same assets may also be used to secure, and we may guaranty, a loan by an affiliate of JPMorgan Chase Bank, N.A. to our Chinese subsidiary for the construction of a new manufacturing line. The Chase Agreement includes customary covenants and also imposes a financial covenant requiring compliance with a minimum fixed charge coverage ratio of 1.00 to 1.00 during certain covenant testing times triggered if availability under the Chase Agreement is below the greater of 10% of the revolving commitment and $8.0 million.

Loans under the Chase Agreement are secured by a lien on substantially all of our and our principal domestic operating subsidiary’s assets.

As of September 30, 2015, there were no borrowings outstanding under our Chase revolving loan facility, and we were in compliance with all covenants under this loan agreement. Total availability under our Chase revolving loan facility was $80.0 million at September 30, 2015, which is subject to adjustment on a monthly basis under our borrowing base calculation.

Fixed asset committed loan facility

On April 6, 2015, SCP entered into a fixed assets committed loan facility (“China Facility”) with Chase China. SCP may make drawings under the China Facility in an aggregate amount up to $18.0 million to finance capital expenditures relating to a product line expansion. Amounts drawn under the China Facility bear interest at the LIBOR rate (or Chase China’s cost of funds if the long term foreign debt quota of Chase China is not available) plus 3.25%. Amounts drawn under the China Facility will be subject to an amortization schedule. Principal payments for any amounts drawn will be repaid in accordance with that schedule, between 36-60 months.

SVB asset based revolving loan facility

On February 13, 2012, we entered into a Loan and Security Agreement with SVB (the “SVB Agreement”). The SVB Agreement provides for a $40.0 million asset based revolving loan facility, with availability determined by a borrowing base consisting of eligible accounts receivable and inventory and subject to certain conditions precedent specified in the SVB Agreement. The SVB Agreement matures on February 13, 2016, at which time all outstanding amounts will become due and payable. Borrowings under the SVB Agreement may be used for general corporate purposes, including funding working capital. Amounts drawn bear an interest rate equal to, at our option, either a Eurodollar rate plus 2.50% per annum or an alternative base rate plus 1.50% per annum. We also pay a commitment fee on undrawn amounts equal to 0.30% per annum. During the continuance of an event of default, at SVB’s option, all obligations will bear interest at a rate per annum equal to 5.00% per annum above the otherwise applicable rate.

Loans under the SVB Agreement are secured by substantially all of our and our principal domestic operating subsidiary’s assets, other than our equity interests in our joint ventures and certain other limited exceptions.

The SVB Agreement contains various customary affirmative and negative covenants. The negative covenants restrict our ability to, among other things, incur additional indebtedness, create or permit to exist liens, make certain investments, dividends and other payments in respect of capital stock, sell assets or otherwise dispose of our property, change our lines of business, or enter into a merger or acquisition, in each case, subject to thresholds and exceptions as set forth in the SVB Agreement. The financial covenants in the original SVB Agreement are limited to maintenance of a minimum adjusted quick ratio and a minimum free cash flow. The SVB Agreement also contains customary events of default, including non-payment of principal, interest and other fees after stated grace periods, violations of covenants, material inaccuracy of representations and warranties, certain bankruptcy and liquidation events, certain material judgments and attachment events, cross-default to other debt in excess of a specified amount and material agreements, failure to maintain certain material governmental approvals, and actual or asserted invalidity of subordination terms, guarantees and collateral, in each case, subject to grace periods, thresholds and exceptions as set forth in the SVB Agreement.

In September 2013, we entered into the Second Loan Modification Agreement (the “Second Modification Agreement”) to the SVB Agreement. The Second Modification Agreement makes certain amendments to the SVB Agreement, including: modifying the calculation methodology of the borrowing base that is used to determine our borrowing availability; eliminating the covenant to maintain a specified level of free cash flow in quarters where we maintain eligible cash balances of $30.0 million or greater and modifying the covenant for the adjusted quick ratio to be tested at the end of each month; and providing us additional flexibility to make certain investments. The Second Modification Agreement did not amend the term of the SVB Agreement, the maximum availability under the SVB Agreement, or the interest rate applicable to amounts drawn under the SVB Agreement.

Concurrent with entering the Chase Agreement, we terminated our existing revolving credit facility with SVB and repaid certain associated fees. Included with the fees was $1.1 million of deferred costs triggered by the early termination of the agreement. This amount is included within interest expense in the condensed consolidated statement of operations in the fourth quarter of 2014. Concurrent with the repayment and termination of the agreement, all liens and security interests against our property that secured the obligations under our existing revolving credit facility were released and discharged.

Chinese loan facilities

SCP had outstanding debt obligations with ABC at the time of the SCP Acquisition. SCP originally entered into two loan contracts with ABC for RMB 83.0 million ($13.6 million) and RMB 37.0 million ($6.1 million) in August 2010 and June 2011, respectively (the “ABC Loans”). In November 2013, we repaid RMB 55.0 million ($9.0 million) of the then outstanding balance. At December 31, 2013, RMB 63.0 million ($10.3 million) of the original loan remains outstanding, and is subject to a repayment schedule, with all amounts due and payable by August 2015. The ABC Loans were used for the construction of the SCP facility and funding of the ongoing operations of SCP up to the date of the SCP Acquisition. Amounts outstanding under the ABC Loans bear an interest rate equal to the benchmark lending interest rate published by the People’s Bank of China. During the term of the loan, the rate is subject to adjustment every three months. The ABC Loans are secured by the property, plant and equipment of SCP. The ABC Loans contain various covenants, including covenants that restrict SCP’s ability to incur additional indebtedness, provide guarantees, pledge or incur liens on assets, enter into merger, consolidation or acquisition transactions, or transfer assets. In addition, the ABC Loans contain financial covenants that require SCP to achieve specified minimum revenue levels and to maintain a specified liability to assets ratio. As of December 31, 2013, the interest rate for the ABC Loans was 6.00%.

On January 2, 2014, we repaid in full all outstanding amounts (RMB 63.0 million, $10.3 million) under the ABC Loans, and the loan contracts were terminated.

Omega credit facilities

Omega has an authorized credit facility (the “Omega operating credit facility”) in the amount of C$8.2 million ($7.3 million) with the NBC. The Omega operating credit facility can be utilized in the form of floating-rate advances for an amount not exceeding C$7.0 million ($6.2 million as of the acquisition date) and advances in the form of letters of guarantee or letters of credit, within that limit for an amount not exceeding C$2.0 million ($1.8 million as of the acquisition date). The Omega operating credit facility can also be utilized in the form of advances to cover Omega’s currency risk for an amount not to exceed C$1.2 million ($1.1 million as of the acquisition date). On October 1, 2014, the Omega operating credit facility had floating-rate advances in the amount of C$1.5 million ($1.4 million) bearing interest at the lender’s prime rate plus 0.50%, (or an effective rate of 3.5%) which we assumed as part of the acquisition. As of December 31, 2014, C$3.3 million ($2.8 million) was outstanding under the Omega operating credit facility.

In July 2014, Omega obtained a C$3.0 million demand loan (the “Omega demand loan”), from the NBC bearing interest at the prime rate of the lender, plus a premium of 1.75% (effective rate 4.75%). The Omega demand loan is secured by all of the assets of Omega for C$3.0 million plus an additional security interest of 20% of this amount, bearing interest at 4.75% per annum and matured in November 2014. We assumed the Omega demand loan ($2.7 million as of the acquisition date) in connection with the acquisition and subsequently extended the maturity date to January 2015. The Omega operating credit facility and the Omega demand loan are secured by a first ranking security interest in the amount of C$8.3 million ($7.4 million as of the acquisition date) in Omega’s inventories, trade receivables and on the intellectual property of Omega, present and future. As of December 31, 2014, C$3.0 million ($2.7 million) was outstanding under the Omega demand loan.

Omega also had C$0.3 million ($0.2 million) outstanding on a decreasing revolving credit facility with the NBC (the “Omega decreasing revolving credit facility”) bearing interest at the prime rate of the lender, plus 1.0% (or an effective rate equal to 4.0%). The Omega decreasing revolving credit facility is secured by a first ranking security interest of C$1.0 million ($0.9 million as of the acquisition date) on the equipment, tooling and office furniture financed by the credit facility.

The Omega credit facilities are subject to certain restrictions, including the obligation to maintain certain financial ratios. As of October 1, 2014, Omega had not met certain of these financial ratios. As a result, the Omega decreasing revolving credit facility was classified as a current liability as of the acquisition date. In January 2015, we paid off all amounts outstanding under the Omega operating credit facility, the Omega demand loan and the Omega decreasing revolving credit facility with available cash on hand. As a result, all amounts outstanding under these instruments are classified as current liabilities at December 31, 2014.

In addition to the above, Omega had five mortgage loans with the BDC (collectively the “Omega mortgages”) which we assumed in connection with the acquisition. The Omega mortgages, which require monthly installments and which are secured by specific Omega buildings and equipment, range in amount from C$0.1 million to C$1.3 million ($0.1 million to $1.1 million as of the acquisition date) and bear interest at the lender’s prime rate (5% as of the acquisition date) plus a premium ranging from 0%—1.5%. The Omega mortgages mature at various times from August 2019 through November 2036.

Aggregate Contractual Obligations

As of September 30, 2015, there were no material changes to the contractual obligations information provided in Item 7 entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K, filed with the SEC on March 16, 2015.

Off-Balance Sheet Arrangements

As of September 30, 2015, we were not party to any off-balance sheet arrangements, nor have we created any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt or operating our business. With the exception of operating leases, we do not have any off-balance sheet arrangements or relationships with entities that are not consolidated into or disclosed on our financial statements that have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources. In addition, we do not engage in trading activities involving non-exchange traded contracts.

Critical Accounting Policies

We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates and assumptions. We have identified the following critical accounting policies:

•

Revenue recognition;

•

Inventories;

•

Income taxes;

•

Stock-based compensation;

•

Valuation and impairment of marketable securities;

•

Product development;

•

Intangible assets;

•

Consolidations; and

•

Goodwill.

For a discussion of critical accounting policies affecting us, see the discussion under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies” and under Note 1 to our consolidated financial statements for the year ended December 31, 2014 included in our Annual Report on Form 10-K filed with the SEC on March 16, 2015.

There have been no other material changes to the Company’s critical accounting policies and estimates since December 31, 2014.

New Accounting Guidance

In September 2015, the FASB issued guidance that eliminates the requirement to restate prior period financial statements for measurement period adjustments. The new guidance requires that the cumulative impact of a measurement period adjustment (including the impact on prior periods) be recognized in the reporting period in which the adjustment is identified. In addition, separate presentation on the face of the income statement or disclosure in the notes to the financial statements is required regarding the portion of the adjustment recorded in current period earnings. We are required to adopt this guidance prospectively for measurement period adjustments that occur after the effective date. This guidance is effective for the Company in the first quarter of 2016. Early adoption is permitted. We have adopted this guidance in the current period. There was no material impact of adoption.

Contingencies

See Note 18. Commitments and Contingencies, and Part II, Item 1. Legal Proceedings for a discussion of contingencies.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Our market risks relate primarily to changes in interest rates and currency fluctuations between the Chinese Renminbi and the US dollar, and between the Canadian dollar and US dollar, as the assets, liabilities and transactions of our international operations are generally recorded in the local currency of each of our legal entities.

The revolving loan facility under our Chase Agreement and substantially all of Omega’s debt facilities bear floating interest rates that are tied to LIBOR or an alternate rate, and therefore, our statements of operations and our cash flows are exposed to changes in interest rates. Based on the amounts outstanding at September 30, 2015, a one percentage point increase in LIBOR would increase our ongoing interest expense by less than $0.1 million per year, and a 10% strengthening of the Canadian dollar relative to the US dollar, would increase our ongoing interest expense by less than $0.1 million per year. We historically have not engaged in hedging activities related to our interest rate or foreign exchange risks.

At September 30, 2015, we had cash and cash equivalents and short-term investments of $25.9 million and $20.2 million, respectively. Our cash and cash equivalents are held primarily in cash and money market funds, and our short-term investments are held primarily in corporate debt securities and commercial paper. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of these investments, we believe that we do not have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates.

We generally record sales and pay our expenses in the local currency of the legal entity that incurs the expense. Substantially all of our business partners that supply us with API, product development services and finished product manufacturing are located in a number of foreign jurisdictions, and we believe those business partners generally incur their respective operating expenses in local currencies. As a result, both we and our business partners may be exposed to currency rate fluctuations and experience an effective increase in operating expenses in the event local currencies appreciate against the U.S. dollar. In this event, the cost of manufacturing product from our SCP facility may increase or such business partners may elect to stop providing us with these services or attempt to pass these increased costs back to us through increased prices for product development services, API sourcing or finished products that they supply to us. Historically we have not used derivatives to protect against adverse movements in currency rates.

We do not have any foreign currency or any other material derivative financial instruments.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures (a) were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Internal Control over Financial Reporting.

Management, together with our Chief Executive Officer and our Chief Financial Officer, evaluated the changes in our internal control over financial reporting during the quarter ended September 30, 2015. We determined that there were no changes in our internal control over financial reporting during the quarter ended September 30, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

On October 13, 2015, the Company and Novartis agreed to settle the Litigation. Pursuant to the terms of the settlement, the Company will pay Novartis $5 million in exchange for a release of claims associated with the 241, 987 and 189 Patents pertaining to the following regulatory submissions: FDA NDA No. 203231, FDA ANDA No. 202828, FDA ANDA No. 202472 and FDA ANDA No. 091493 (collectively the “Regulatory Submissions”), and acquire a license to sell the zoledronic acid products as approved by their Regulatory Submissions (excluding sales of product manufactured under FDA ANDA No. 202472 after December 31, 2014) in the United States. The settlement is subject to confirmation by the US Federal Trade Commission. Concurrent with the Novartis settlement, the Company is entitled to receive $1.5 million from Info and Actavis, representing their collective share of the $5 million.

At this time, there are no other proceedings of which we are aware that are considered likely to have a material adverse effect on the consolidated financial position or results of operations.

Item 1A. Risk Factors.

There were no material changes during the three months ended September 30, 2015 to the risk factors previously disclosed under Item 1A entitled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the SEC on March 16, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities during the Quarter ended September 30, 2015

There are currently no share repurchase programs authorized by our Board of Directors. We did not repurchase any shares of our common stock during the quarter ended September 30, 2015.

Recent Sales of Unregistered Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits.


Exhibit Number		Description

3.1		Certificate of Incorporation of Sagent Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.3 in the Company’s Registration Statement on Form S-1, as amended (File Nos. 333-170979 and 333-173597)).

3.2		Bylaws of Sagent Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.4 in the Company’s Registration Statement on Form S-1, as amended (File Nos. 333-170979 and 333-173597)).

3.3		Certificate of Amendment to the Certificate of Incorporation (Incorporated by reference to Exhibit 3.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 5, 2014).

10.1*		Employment Agreement dated August 3, 2015, by and among Sagent Pharmaceuticals, Inc., and Allan Oberman.

31.1*		Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2*		Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended

32.1*		Certifications pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.1		The following materials from Sagent’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 are formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (ii) the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2015 and 2014, (iv) the Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014, (v) Notes to the Condensed Consolidated Financial Statements, tagged as blocks of text and (vi) document and entity information.

* Filed herewith

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SAGENT PHARMACEUTICALS INC.

/s/ Jonathon M. Singer

Jonathon M. Singer

Executive Vice President and Chief Financial Officer

November 3, 2015

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company